NCT06206278 2024-08-14
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
LianBio LLC
Phase 2 Terminated
Clinical Trials
5 trialsNCT02150967 2023-07-03
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
QED Therapeutics, a BridgeBio company
Phase 2 Terminated
NCT03510455 2021-04-08
BGJ398 for the Treatment of Tumor-Induced Osteomalacia
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02160041 2019-06-18
CBGJ398XUS04
Novartis
Phase 2 Terminated
NCT02706691 2019-04-16
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
Phase 2 Terminated